Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice

Neurobiology of Disease

Volumn 35, Issue 3, 2009, Pages 406-414

  Tong, Xin Kang ^a   Nicolakakis, Nektaria ^a   Fernandes, Priscilla ^a   Ongali, Brice ^a   Brouillette, Jonathan ^b   Quirion, Rémi ^b   Hamel, Edith ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Amyloid beta; Cerebral blood vessels; Cholinergic; Memory; Oxidative stress; Statin

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CALCITONIN GENE RELATED PEPTIDE; N(G) NITROARGININE; SIMVASTATIN; SUPEROXIDE;

AGED; AGING; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD VESSEL REACTIVITY; BRAIN ARTERY; BRAIN BLOOD FLOW; BRAIN FUNCTION; CELL ACTIVATION; CHOLINERGIC ACTIVITY; CONTROLLED STUDY; DISEASE COURSE; INHIBITION KINETICS; LOW DRUG DOSE; MAZE TEST; MOUSE; NERVE CELL; NERVOUS SYSTEM INFLAMMATION; NEURITE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SENILE PLAQUE; SPATIAL MEMORY; TRANSGENIC MOUSE; TREATMENT RESPONSE;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CEREBROVASCULAR CIRCULATION; DISEASE MODELS, ANIMAL; ENCEPHALITIS; HUMANS; LEARNING DISORDERS; MEMORY DISORDERS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEUROIMMUNOMODULATION; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PLAQUE, AMYLOID; PROTEASE NEXINS; RECEPTORS, CELL SURFACE; SIMVASTATIN; SPACE PERCEPTION;

EID: 68149148938     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2009.06.003     Document Type: Article

References (58)

1. Aucoin J.S., Jiang P., Aznavour N., Tong X.K., Buttini M., Descarries L., and Hamel E. Selective cholinergic denervation, independent from oxidative stress, in a mouse model of Alzheimer's disease. Neuroscience 132 (2005) 73-86
2. Brendza R.P., Bacskai B.J., Cirrito J.R., Simmons K.A., Skoch J.M., Klunk W.E., Mathis C.A., Bales K.R., Paul S.M., Hyman B.T., and Holtzman D.M. Anti-Aβ antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J. Clin. Invest. 115 (2005) 428-433
3. Breteler M.M. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol. Aging 21 (2000) 153-160
4. Carlsson C.M., Gleason C.E., Hess T.M., Moreland K.A., Blazel H.M., Koscik R.L., Schreiber N.T., Johnson S.C., Atwood C.S., Puglielli L., Hermann B.P., McBride P.E., Stein J.H., Sager M.A., and Asthana S. Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease. J. Alzheimer's Dis. 13 (2008) 187-197
5. Chauhan N.B., Siegel G.J., and Feinstein D.L. Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRND8 brain. Neurochem. Res. 29 (2004) 1897-1911
6. Cheng I.H., Scearce-Levie K., Legleiter J., Palop J.J., Gerstein H., Bien-Ly N., Puoliväli J., Lesné S., Ashe K.H., Muchowski P.J., and Mucke L. Accelerating amyloid-β fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J. Biol. Chem. 282 (2007) 23818-23828
7. Cimino M., Gelosa P., Gianella A., Nobili E., Tremoli E., and Sironi L. Statins: multiple mechanisms of action in the ischemic brain. Neuroscientist 13 (2007) 208-213
8. Cordle A., and Landreth G. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate β-amyloid-induced microglial inflammatory responses. J. Neurosci. 25 (2005) 299-307
9. de la Torre J.C. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol. 3 (2004) 184-190
10. Delbosc S., Morena M., Djouad F., Ledoucen C., Descomps B., and Cristol J.P. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes. J. Cardiovasc. Pharmacol. 40 (2002) 611-617
11. Didion S.P., Ryan M.J., Baumbach G.L., Sigmund C.D., and Faraci F.M. Superoxide contributes to vascular dysfunction in mice that express human renin and angiotensinogen. Am. J. Physiol., Heart Circ. Physiol. 283 (2002) H1569-H1576
12. Elhusseiny A., and Hamel E. Muscarinic-but not nicotinic-acetylcholine receptors mediate a nitric oxide-dependent dilation in brain cortical arterioles: a possible role for the M5 receptor subtype. J. Cereb. Blood Flow Metab. 20 (2000) 298-305
13. Erdös B., Snipes J.A., Tulber C.D., Katakam P., Miller A.W., and Busija D.W. Rosuvastatin improves cerebrovascular function in Zucker obese rats by inhibiting NAD(P)H oxidase-dependent superoxide production. Am. J. Physiol., Heart Circ. Physiol. 290 (2006) H1264-H1270
14. Friedhoff L.T., Cullen E.I., Geoghagen N.S., and Buxbaum J.D. Treatment with controlled-release lovastatin decreases serum concentrations of human β-amyloid (Aβ) peptide. Int. J. Neuropsychopharmacol. 4 (2001) 127-130
15. Garcia-Alloza M., Dodwell SA., Meyer-Luehmann M., Hyman B.T., and Bacskai B.J. Plaque-derived oxidative stress mediates distorted neurite trajectories in the Alzheimer mouse model. J. Neuropathol. Exp. Neurol. 65 (2006) 1082-1089
16. Haydon P.G., and Carmignoto G. Astrocyte control of synaptic transmission and neurovascular coupling. Physiol. Rev. 86 (2006) 1009-1031
17. Hong K.W., Yoo S.E., Yu S.S., Lee J.Y., and Rhim B.Y. Pharmacological coupling and functional role for CGRP receptors in the vasodilation of rat pial arterioles. Am. J. Physiol. 270 (1996) H317-H323
18. Iadecola C., Zhang F., Niwa K., Eckman C., Turner S.K., Fischer E., Younkin S., Borchelt D.R., Hsiao K.K., and Carlson G.A. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat. Neurosci. 2 (1999) 157-161
19. Infanger D.W., Sharma R.V., and Davisson R.L. NADPH oxidases of the brain: distribution, regulation, and function. Antioxid. Redox Signal. 8 (2006) 1583-1596
20. Jick H., Zornberg G.L., Jick S.S., Seshadri S., and Drachman D.A. Statins and the risk of dementia. Lancet 356 (2000) 1627-1631
21. Johnson-Anuna L.N., Eckert G.P., Franke C., Igbavboa U., Müller W.E., and Wood W.G. Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein. J. Neurochem. 101 (2007) 77-86
22. Kaesemeyer W.H., Caldwell R.B., Huang J., and Caldwell R.W. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J. Am. Coll. Cardiol. 33 (1999) 234-241
23. Kalaria R.N., and Pax A.B. Increased collagen content of cerebral microvessels in Alzheimer's disease. Brain Res. 705 (1995) 349-352
24. Kitazono T., Heistad D.D., and Faraci F.M. Role of ATP-sensitive K+ channels in CGRP-induced dilatation of basilar artery in vivo. Am. J. Physiol. 265 (1993) H581-H585
25. Lesné S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., and Ashe K.H. A specific amyloid-β protein assembly in the brain impairs memory. Nature 440 (2006) 352-357
26. Lesné S., Kotilinek L., and Ashe K.H. Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function. Neuroscience 151 (2008) 745-749
27. Li L., Cao D., Kim H., Lester R., and Fukuchi K. Simvastatin enhances learning and memory independent of amyloid load in mice. Ann. Neurol. 60 (2006) 729-739
28. Li G., Sokal I., Quinn J.F., Leverenz J.B., Brodey M., Schellenberg G.D., Kaye J.A., Raskind M.A., Zhang J., Peskind E.R., and Montine T.J. CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 69 (2007) 631-639
29. Miller A.W., Tulbert C.D., and Busija D.W. Rosuvastatin treatment reverses impaired coronary artery vasodilation in fructose-fed, insulin-resistant rats. Am. J. Physiol., Regul. Integr. Comp. Physiol. 287 (2004) R157-R160
30. Mucke L., Masliah E., Yu G.Q., Mallory M., Rockenstein E.M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., and McConlogue L. High-level neuronal expression of Aβ1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20 (2000) 4050-4058
31. Nicolakakis N., Aboulkassim T., Ongali B., Lecrux C., Fernandes P., Rosa-Neto P., Tong X.K., and Hamel E. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J. Neurosci. 28 (2008) 9287-9296
32. Niwa K., Younkin L., Ebeling C., Turner S.K., Westaway D., Younkin S., Ashe K.H., Carlson G.A., and Iadecola C. Aβ1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 9735-9740
33. Otto A., Fontain J., Tschirhart E., Fontaine D., and Berkenboom G. Rosuvastatin treatment protects against nitrate-induced oxidative stress in eNOS knockout mice: implication of the NAD(P)H oxidase pathway. Br. J. Pharmacol. 148 (2006) 544-552
34. Palmer A.M., Gopaul N., Dhir S., Thomas C.R., Poston L., and Tribe R.M. Endothelial dysfunction in streptozotocin-diabetic rats is not reversed by dietary probucol or simvastatin supplementation. Diabetologia 41 (1998) 157-164
35. Palop J.J., Jones B., Kekonius L., Chin J., Yu G.Q., Raber J., Masliah E., and Mucke L. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 9572-9577
36. Park L., Zhou P., Pitstick R., Capone C., Anrather J., Norris E.H., Younkin L., Younkin S., Carlson G., McEwen B.S., and Iadecola C. Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 1347-1352
37. Roher A.E., Esh C., Kokjohn T.A., Kalback W., Luehrs D.C., Seward J.D., Sue L.I., and Beach T.G. Circle of Willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 2055-2062
38. Ruitenberg A., den Heijer T., Bakker S.L., van Swieten J.C., Koudstaal P.J., Hofman A., and Breteler M.M. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann. Neurol. 57 (2005) 789-794
39. Saheki A., Terasaki T., Tamai I., and Tsuji A. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm. Res. 11 (1994) 305-311
40. Shinozaki K., Nishio Y., Ayajiki K., Yoshida Y., Masada M., Kashiwagi A., and Okamura T. Pitavastatin restores vascular dysfunction in insulin-resistant state by inhibiting NAD(P)H oxidase activity and uncoupled endothelial nitric oxide synthase-dependent superoxide production. J. Cardiovasc. Pharmacol. 49 (2007) 122-130
41. Simons M., Schwärzler F., Lütjohann D., von Bergmann K., Beyreuther K., Dichgans J., Wormstall H., Hartmann T., and Schulz J.B. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann. Neurol. 52 (2002) 346-350
42. Sorescu D., Weiss D., Lassègue B., Clempus R.E., Szöcs K., Sorescu G.P., Valppu L., Quinn M.T., Lambeth J.D., Vega J.D., Taylor W.R., and Griendling K.K. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 105 (2002) 1429-1435
43. Sparks D.L., Sabbagh M., Connor D., Soares H., Lopez J., Stankovic G., Johnson-Traver S., Ziolkowski C., and Browne P. Statin therapy in Alzheimer's disease. Acta Neurol. Scand. Suppl. 185 (2006) 78-86
44. Sun X., He G., Qing H., Zhou W., Dobie F., Cai F., Staufenbiel M., Huang L.E., and Song W. Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 18727-18732
45. Tong X.K., Nicolakakis N., Kocharyan A., and Hamel E. Vascular remodeling versus amyloid β-induced oxidative stress in the cerebrovascular dysfunctions associated with Alzheimer's disease. J. Neurosci. 25 (2005) 11165-11174
46. Trollor J.N., Sachdev P.S., Haindl W., Brodaty H., Wen W., and Walker B.M. Regional cerebral blood flow deficits in mild Alzheimer's disease using high resolution single photon emission computerized tomography. Psychiatry Clin. Neurosci. 59 (2005) 280-290
47. van de Ree M.A., Huisman M.V., de Man F.H., van der Vijver J.C., Meinders A.E., and Blauw G.J. Impaired endothelium-dependent vasodilation in type 2 diabetes mellitus and the lack of effect of simvastatin. Cardiovasc. Res. 52 (2001) 299-305
48. Van Dorpe J., Smeijers L., Dewachter I., Nuyens D., Spittaels K., Van den Haute C., Mercken M., Moechars D., Laenen I., Kuiperi C., Bruynseels K., Tesseur I., Loos R., Vanderstichele H., Checler F., Sciot R., and Van Leuven F. Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the London mutant of human APP in neurons. Am. J. Pathol. 157 (2000) 1283-1298
49. Vinters H.V., Secor D.L., Read S.L., Frazee J.G., Tomiyasu U., Stanley T.M., Ferreiro J.A., and Akers M.A. Microvasculature in brain biopsy specimens from patients with Alzheimer's disease: an immunohistochemical and ultrastructural study. Ultrastruct. Pathol. 18 (1994) 333-348
50. Wang H., Lynch J.R., Song P., Yang H.J., Yates R.B., Mace B., Warner D.S., Guyton J.R., and Laskowitz D.T. Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury. Exp. Neurol. 206 (2007) 59-69
51. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., and Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57 (2000) 1439-1443
52. Wong G.H., and Goeddel D.V. Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science 242 (1988) 941-944
53. Yamada M., Lamping K.G., Duttaroy A., Zhang W., Cui Y., Bymaster F.P., McKinzie D.L., Felder C.C., Deng C.X., Faraci F.M., and Wess J. Cholinergic dilation of cerebral blood vessels is abolished in M(5) muscarinic acetylcholine receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 14096-14101
54. ATP channel. Eur. J. Heart Fail. 9 (2007) 30-36
55. Yemisci M., Ay H., Kocaefe C., Qui J., Topalkara K., Ozgüç M., Kirazli S., Ozcebe O., Moskowitz M.A., and Dalkara T. Statin potentiates human platelet eNOS activity without enhancing eNOS mRNA and protein levels. Cerebrovasc. Dis. 26 (2008) 190-198
56. Zacco A., Togo J., Spence K., Ellis A., Lloyd D., Furlong S., and Piser T. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J. Neurosci. 23 (2003) 11104-11111
57. Zhang L., Zhang Z.G., Ding G.L., Jiang Q., Liu X., Meng H., Hozeska A., Zhang C., Li L., Morris D., Zhang R.L., Lu M., and Chopp M. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat. Circulation 112 (2005) 3486-3494
58. Zlokovic B.V. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 28 (2005) 202-208